APPENDICURE

Innovations in the Treatment of Appendix Cancer

BLOG

Category: Education

  • Why Some Men With Appendix Cancer Still Aren’t Getting CA125 Testing

    New research is raising an uncomfortable question. Are some appendix cancer patients, especially men, missing an important tumor marker because of an outdated assumption about who it’s for? For years, appendix cancer patients have had their bloodwork monitored with tumor markers like CEA and CA19-9. CA125, historically associated with ovarian cancer, has not always been…

  • What Tumor Markers Tell Us Before and After CRS

    A new MD Anderson study of 376 cytoreductive surgeries finds that CEA, CA19-9, and CA125, considered together and tracked over time, give surgeons and patients meaningful information about disease burden, surgical outcomes, and the years that follow. FROM OUR COMMUNITYMany Appendicure members have watched their CEA, CA19-9, or CA125 numbers shift in the weeks before…

  • What You Need to Know About Stomas in CRS and HIPEC

    If you are heading into CRS and HIPEC for appendix cancer, there is a conversation worth having with your surgical team before the day of surgery, and it is the one most patients tell us they wish they had pushed harder for: the stoma conversation. A retrospective study published this spring in Medical Research Archives…

  • Life After CRS/HIPEC Surgery & GLP-1 Update That Looks Promising

    What Real Patients Told Us About Their Experience Based on: Bleicher et al., Annals of Surgical Oncology (March 2026) I posted this in March when the study came out, but wanted to add in some new information I’ve learned in regard to GLP-1’s. Keep reading as I’ve added in that information towards the end. When…

  • Your CDK4/6 Story – Ibrance, Verzenio, or Kisqali – Could Change the Guidelines

    For the past several weeks, I have been collecting information from patients in our community who are taking Ibrance, Verzenio, or Kisqali for appendix cancer. The drugs are called CDK4/6 inhibitors. They are FDA-approved for breast cancer. They are not FDA-approved for our disease. And yet, at major cancer centers around the country, oncologists are…

  • When Surveillance Feels Like a Placeholder: A Closer Look at LAMN Follow-Up After Appendectomy

    Why a patient asking “is this actually a plan?” is asking the right question, and what the published protocols say. This post was already drafted. I had been chipping away at it for a few days because I keep hearing different versions of the same frustration from LAMN patients, and I had not yet seen…